Impressum Bookmark Kontakt Sitemap

Solide Tumoren - Gesicht und HNO-Bereich - Kopf-Hals-Karzinome -
Weiterführende Informationen

Kopf-Hals-Karzinome

Leitlinien

 

In Überarbeitung

 

Studien

 

www.studien.de oder www.eortc.be

 

Literatur

 

  1. Kurita H et al: Impact of different surgical margin conditions on local recurrence of oral squamous cell carcinoma. Oral Oncol. 2010; 46: 814–7
  2. Nason RW et al: What is the adequate margin of surgical resection in oral cancer? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107: 625–9
  3. Stenson KM et al: The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 2000; 126: 950–6
  4. Grégoire V et al: CT-based delineation of lymph node levels and related CTVs in the node- negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. Radiother Oncol 2003; 69: 227–236
  5. Nangia S et al: Selective nodal irradiation for head-and-neck cancer using IMRT application of RTOG consensus guidelines in routine clinical practice. Int J Rad Oncol Biol Phys 2010; 76: 146–153
  6. Ang KK et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas. J Clin Oncol. 2011; 29 (suppl) #5500
  7. Lorch JH et al: Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous cell cancer of the head and neck: long term results of the TAX324 randomised phase 3 trial. Lancet Oncol 2011; 12: 153–9
  8. Machtay M et al: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG Analysis. J Clin Oncol 2008; 26: 3582–9
  9. Koutcher L et al: Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Rad Oncol Biol Phys 2010; published online
  10. McDonald MW et al: Risk of carotid blowout after reirradiation of the head and neck: a systematic review: Int J Radiat Oncol Biol Phys 2011; published online
  11. Zundel T et al: Comparison of physical examination and fluorodeoxyglucose positron emission tomography/computed tomography  4 – 6 months after radiotherapy to assess residual head and neck cancer. Int J Rad Oncol Biol Phys 2011; published online
  12. Bonner JA et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567–78
  13. Bonner JA et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11: 21–8
  14. Forastiere AA et al: Head and neck cancers. J Natl Compr Canc Netw 2005; 3: 316–91
  15. Haddad RI et al: Recent advances in head and neck cancer. N Engl J Med 2008; 359: 1143–54
  16. Hitt R et al: Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27: 15s (suppl) #6009
  17. Hoebers F et al: Reirradiation for head-and-Neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 2011 (published online).
  18. Krebs in Deutschland. 6. überarbeitete, aktualisierte Ausgabe. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das RKI. Saarbrücken, 2008
  19. Lefebre JL: Laryngopharyngeal Cancer. The international federation of head and neck oncologic societies, global continuing education program, Rome 2008
  20. Joseph BS, Pai SI. Human papillomavirus and the shifting trends in head and neck cancer. 2011 ASCO-Annual Meeting Educational Book
  21. Lefebvre J et al: Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. J Clin Oncol 2009; 27: 15s: (suppl) #6010)
  22. Mendenhall WM et al: Radiotherapy for head and neck cancer – is the “next level” down? Int J Radiat Oncol Biol Phys 2009; 73: 645–6
  23. Nutting CM et al: Parotid sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicenter randomised controlled trial. The Lancet Oncol 2011; 12: 127–136
  24. Pignon JP et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14
  25. Remenar E et al: A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971. J Clin Oncol 2006; 24 (suppl 18): #A-5516
  26. Seiwert TY, Cohen EEW: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341–8
  27. Seiwert TY. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). J Clin Oncol 29: 2011 (suppl) #5519
  28. Shah JP, Gil Z: Current concepts in management of oral cancer surgery. Oral Oncol 2009; 45: 394–401
  29. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw 2011; 9: 665-73
  30. Vermorken JB et al: Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008;359: 1116–27
  31. Argiris A, Kotsakis A. Update on targeted therapies for recurrent or metastatic squamous cell carcinoma of the head and neck. 2011 ASCO Annual Meeting Educational Book